Chest
Original ResearchMycobacterial DiseaseFactors Associated With Failure To Complete Isoniazid Treatment for Latent Tuberculosis Infection in Rhode Island
Section snippets
Study Population
Patients who initiated INH therapy for the treatment of LTBI at the RISE TB Clinic between January 2003 and December 2003 were included in the study. The RISE TB Clinic is dedicated to the management of TB and receives referrals from primary care sites across the entire state. Patients who met the criteria for a positive tuberculin skin test result according to standard guidelines,8 and had no symptoms and no chest radiographic findings suggestive of active TB were considered to have LTBI. The
Study Population
The medical records of 873 persons who were evaluated for LTBI during the study period at RISE TB Clinic were reviewed. A total of 28 persons were excluded from further analysis for the reasons shown in Figure 1. The referral sources included community health centers (42.5%), private physicians (12.9%), the Department of Health (10.2%), employer (4.9%), civil surgeon (2.9%), and other sites including schools and drug rehabilitation centers (5.8%). Of the 845 patients who were considered as
Discussion
In this study, which was conducted in a clinic dedicated to the management of TB in Rhode Island, 82% of the patients with LTBI who were eligible initiated INH therapy, and 62% of those initiating therapy completed it. Our completion rate is comparable to rates that have been reported12,14,16 for 6 months of INH therapy, and were much higher than the 19% rate reported for a similar regimen given in a 2006 study17 in Boston. We were unable to examine what components of the program led to the
References (27)
- et al.
Treatment of latent tuberculosis infection: challenges and prospects
Clin Chest Med
(2005) - et al.
Somatic complaints and isoniazid (INH) side effects in Latino adolescent with latent tuberculosis infection (LTBI)
Patient Educ Couns
(2004) - et al.
Patients' beliefs about prescribed medicines and their role in adherence to treatment in chronic physical illness
J Psychoomat Res
(1999) - et al.
The global burden of tuberculosis: estimated incidence, prevalence, and mortality by country
JAMA
(1999) WHO report 2007: global tuberculosis control; surveillance, planning, financing
The global plan to stop TB, 2006–2015
A strategic plan for elimination of tuberculosis in the United States
MMWR Morb Mortal Wkly Rep
(1989)Tuberculosis elimination revisited: obstacles, opportunites and a renewed commitment; Advisory Council for the Elimination of Tuberculosis (ACET)
MMWR Morb Mortal Wkly Rep
(1999)Ending neglect: the elimination of tuberculosis in the United States
(2000)- Bennett DE, Courval JM, Onorato IM, et al. Prevalence of TB infection in the US population, 1999–2000 [abstract]. Paper...
Targeted tuberculin testing and treatment of latent tuberculosis infection
Am J Respir Crit Care Med
Priorities for the treatment of latent tuberculosis infection in the United States
N Engl J Med
Controlled chemoprophylaxis trials in tuberculosis: a general review
Adv Tuberc Res
Cited by (61)
Risk factors affecting the failure to complete treatment for patients with latent tuberculosis infection in Tokyo, Japan
2020, Journal of Infection and ChemotherapyDevelopment and description of a theory-driven, evidence-based, complex intervention to improve adherence to treatment for tuberculosis in the UK: the IMPACT study
2024, Health Psychology and Behavioral MedicineConsiderations for the Use of Long-Acting and Extended-Release Agents during Pregnancy and Lactation
2022, Clinical Infectious DiseasesDevelopment of a multivariate prediction model to identify individual case safety reports which require clinical review
2022, Pharmacoepidemiology and Drug SafetyOutcomes of latent tuberculosis infection treatment in Istanbul
2022, International Journal of MycobacteriologySelf-reported engagement in care among U.S. residents with latent tuberculosis infection: 2011-2012
2021, Annals of the American Thoracic Society
The authors have reported to the ACCP that no significant conflicts of interest exist with any companies/organizations whose products or services may be discussed in this article.
Dr. Kwara was supported by Rhode Island Foundation grant No. 20030199 and National Institutes of Health developmental grant No. K23 AI071760.